Evidence map›Paper›PMID 35777367›Full record

Trial reportStatistics in medicine2022

Bayesian local exchangeability design for phase II basket trials.

Yilin Liu, Michael Kane, Denise Esserman, Ondrej Blaha, Daniel Zelterman, Wei Wei

Abstract readClinical Trial, Phase II
In one paragraph

Trial report in Statistics in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yilin LiuDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0001-9971-1766
Michael KaneDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Denise EssermanDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0003-1326-9618
Ondrej BlahaDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Daniel ZeltermanDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Wei WeiDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0003-1263-5620

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI RUTH HALABAN · 2006 to 2026
$43.9M
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1M
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI BURTNESS, BARBARA · 2020 to 2024
$11.8M
Targeting DNA Repair for Cancer Therapy.R35CA197574 · NCI · YALE UNIVERSITY · PI PETER M GLAZER · 2017 to 2026
$8.6M
Oncometabolites, DNA Repair, and CancerR01ES005775 · NIEHS · YALE UNIVERSITY · PI PETER M GLAZER · 1998 to 2026
$8.0M
Meeting Community Needs Across the Prevention SpectrumU48DP005023 · DP · YALE UNIVERSITY · PI DUFFANY, KATHLEEN O'CONNOR · 2014 to 2018
$3.9M
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.U01CA235747 · NCI · YALE UNIVERSITY · PI NGUYEN, DON X, POLITI, KATERINA ABIGAIL · 2019 to 2023
$3.9M
Individualized monitoring of treatment response and resistance in patients with metastatic melanomaR01CA223481 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MURTAZA, MUHAMMED · 2018 to 2022
$2.0M
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer TherapyR01CA168733 · NCI · YALE UNIVERSITY · PI GLAZER, PETER M · 2013 to 2017
$1.7M
Bifunctional Antibodies for Melanoma TherapyR01CA177719 · NCI · YALE UNIVERSITY · PI GLAZER, PETER M · 2014 to 2016
$1.3M
NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1TR001863NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA121974NCI NIH HHS P50 CA196530NIH HHS P30-CA16359NIH HHS P50-CA121974NIH HHS P50-CA196530NIH HHS P50-DE030707-01NIH HHS R01-CA168733NIH HHS R01-CA177719NIH HHS R01-CA223481NIH HHS R01-ES005775NIH HHS R35-CA197574NIH HHS R41-A120546NIH HHS U01-CA235747NIH HHS U48-DP005023NIH HHS UM1-CA18668
6 · The paper itself

Abstract

We propose an information borrowing strategy for the design and monitoring of phase II basket trials based on the local multisource exchangeability assumption between baskets (disease types). In our proposed local-MEM framework, information borrowing is only allowed to occur locally, that is, among baskets with similar response rate and the amount of information borrowing is determined by the level of similarity in response rate, whereas baskets not considered similar are not allowed to share information. We construct a two-stage design for phase II basket trials using the proposed strategy. The proposed method is compared to competing Bayesian methods and Simon's two-stage design in a variety of simulation scenarios. We demonstrate the proposed method is able to maintain the family-wise type I error rate at a reasonable level and has desirable basket-wise power compared to Simon's two-stage design. In addition, our method is computationally efficient compared to existing Bayesian methods in that the posterior profiles of interest can be derived explicitly without the need for sampling algorithms. R scripts to implement the proposed method are available at https://github.com/yilinyl/Bayesian-localMEM.

Indexed as

AlgorithmsResearch DesignBayes TheoremComputer SimulationHumansadaptive designBayesian analysisclusteringmaster protocoloncology

Identifiers

PMID35777367
PMCPMC10279458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.